Richard Adcock Biography and Net Worth

CEO of ImmunityBio

Richard (Rich) Adcock was named Chief Executive Officer of ImmunityBio in January 2021. Formerly CEO of NantKwest, he has held leadership positions in healthcare for nearly 30 years and is recognized for his expertise in building cultures focused on rapid, strategic innovation. He is a Six Sigma Master Black Belt, ensuring that the execution of those strategies is accompanied by strong quality systems throughout the enterprise. Previously, Adcock was CEO of Verity Health, where he led a successful restructuring event. He began his career in 1992 as a co-founder and Vice President of Research and Development for Micro Medical Systems, pioneering the development of early Cardiology Electronic Medical Records. Adcock assumed leadership roles in healthcare innovation following the company’s acquisition by GE Healthcare in 1999. He subsequently earned an MBA in Healthcare Management and joined Sanford Health where he served as President and later as Chief Innovation Officer.

How old is Richard Adcock?: Mr. Adcock is currently 55 years old. There are 6 older executives and no younger executives at ImmunityBio. The oldest executive at ImmunityBio is Dr. Patrick Soon-Shiong F.A.C.S., FRCS, who is 71 years old. Learn More on Richard Adcock's age.
How do I contact Richard Adcock?: The corporate mailing address for Mr. Adcock and other ImmunityBio executives is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. ImmunityBio can also be reached via phone at (858) 633-0300 and via email at [email protected]. Learn More on Richard Adcock's contact information.
Has Richard Adcock been buying or selling shares of ImmunityBio?: Richard Adcock has not been actively trading shares of ImmunityBio in the last ninety days. Most recently, on Friday, October 8th, Richard Adcock bought 1,930 shares of ImmunityBio stock. The stock was acquired at an average cost of $8.81 per share, with a total value of $17,003.30. Learn More on Richard Adcock's trading history.
Who are ImmunityBio's active insiders?: ImmunityBio's insider roster includes Richard Adcock (CEO), Michael Blaszyk (Director), Cheryl Cohen (Director), David Sachs (CFO), and Barry Simon (Director). Learn More on ImmunityBio's active insiders.

Richard Adcock Insider Trading History at ImmunityBio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/8/2021	Buy	1,930	$8.81	$17,003.30

Richard Adcock Buying and Selling Activity at ImmunityBio

ImmunityBio Company Overview

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Today's Range

Now: $2.81

$2.76

$2.83

50 Day Range

MA: $4.54

$2.83

$6.17

2 Week Range

Now: $2.81

$2.76

$10.53

Volume

1,300,602 shs

Average Volume

5,040,906 shs

Market Capitalization

$1.96 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Trump’s Sending THIS Crypto Higher on Purpose

From Crypto 101 Media | Ad

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW